Sulforaphane induces CYP1A1 mRNA, protein, and catalytic activity levels via an AhR-dependent pathway in murine hepatoma Hepa 1c1c7 and human HepG2 cells.
Level 5 - mechanism / opinion, no new human data
In vitro cell culture study (preclinical bench research)
PubMed 19013013 · doi:10.1016/j.canlet.2008.10.003
What was done
Murine hepatoma (Hepa 1c1c7) and human hepatoma (HepG2) cell lines were treated with various concentrations of sulforaphane across multiple time points. Researchers assessed Cyp1a1/CYP1A1 mRNA, protein, and catalytic activity levels. Transcriptional regulation was evaluated using the RNA polymerase inhibitor actinomycin D and assays for aryl hydrocarbon receptor (AhR) transformation and xenobiotic response element (XRE) binding, alongside post-transcriptional mRNA stability assessments.
What was found
Sulforaphane induced CYP1A1 mRNA expression in a dose- and time-dependent manner, beginning as early as 1 hour after treatment (specific concentrations and numerical fold-changes were not reported in the abstract). Parallel increases occurred in CYP1A1 protein and catalytic activity. Actinomycin D completely abolished sulforaphane-induced Cyp1a1 mRNA elevation. Sulforaphane induced AhR transformation and subsequent binding to XRE, but did not alter the degradation rate of existing Cyp1a1 mRNA transcripts.
Why it matters
These findings show that sulforaphane can directly induce the phase I bioactivating enzyme CYP1A1 via an AhR-dependent pathway, clarifying that its bioactivity extends beyond the classical induction of phase II detoxification enzymes.
Limits
The study was conducted entirely in vitro in transformed cancer cell lines (Hepa 1c1c7 and HepG2), which may not reflect non-transformed tissue physiology or in vivo pharmacokinetics. No quantitative data, such as doses tested, effect sizes, or variance, were reported in the abstract.
Cited by
- context Sulforaphane slows down phase I detoxification and speeds up phase II detoxification.